Public concerns about interactions between drugmakers and doctors are
unlikely to go away even tough companies are obliged to disclose payments
to individual doctors. Similar rules are set to take effect in Europe
in 2016.
In the meantime oversight authorities
all over the worlds are looking for cases to prosecute under the U.S.
Foreign Corrupt Practices Act (FCPA) and the UK Bribery Act, which prohibit
payments to government officials, including state-employed doctors, to
obtain business overseas.
See
attached presentation on the Background of the GSK Case
